- Home
- LTH vs IOVA Comparison
LTH vs IOVA Comparison
Compare LTH & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTH
- IOVA
- Stock Information
- Founded
- LTH 1992
- IOVA 2007
- Country
- LTH United States
- IOVA United States
- Employees
- LTH N/A
- IOVA N/A
- Industry
- LTH Hotels/Resorts
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LTH Consumer Discretionary
- IOVA Health Care
- Exchange
- LTH Nasdaq
- IOVA Nasdaq
- Market Cap
- LTH 6.4B
- IOVA 975.1M
- IPO Year
- LTH 2021
- IOVA N/A
- Fundamental
- Price
- LTH $28.02
- IOVA $2.30
- Analyst Decision
- LTH Buy
- IOVA Buy
- Analyst Count
- LTH 11
- IOVA 11
- Target Price
- LTH $35.50
- IOVA $11.90
- AVG Volume (30 Days)
- LTH 1.9M
- IOVA 10.8M
- Earning Date
- LTH 10-23-2025
- IOVA 11-06-2025
- Dividend Yield
- LTH N/A
- IOVA N/A
- EPS Growth
- LTH 93.31
- IOVA N/A
- EPS
- LTH 1.03
- IOVA N/A
- Revenue
- LTH $2,824,027,000.00
- IOVA $241,525,000.00
- Revenue This Year
- LTH $14.61
- IOVA $67.40
- Revenue Next Year
- LTH $10.85
- IOVA $56.32
- P/E Ratio
- LTH $27.01
- IOVA N/A
- Revenue Growth
- LTH 17.25
- IOVA 636.99
- 52 Week Low
- LTH $21.49
- IOVA $1.64
- 52 Week High
- LTH $34.99
- IOVA $12.51
- Technical
- Relative Strength Index (RSI)
- LTH 46.68
- IOVA 50.67
- Support Level
- LTH $28.14
- IOVA N/A
- Resistance Level
- LTH $29.49
- IOVA $2.46
- Average True Range (ATR)
- LTH 0.68
- IOVA 0.14
- MACD
- LTH 0.01
- IOVA -0.09
- Stochastic Oscillator
- LTH 34.67
- IOVA 92.00
About LTH Life Time Group Holdings Inc.
Life Time Group Holdings Inc is a lifestyle and leisure brand offering health, fitness, and wellness experiences to a community. It is engaged in designing, building, and operating distinctive and large, multi-use sports and athletic, professional fitness, family recreation, and spa centers in a resort-like environment, principally in residential locations of metropolitan areas in the United States and Canada.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.